These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
584 related articles for article (PubMed ID: 10769646)
1. Cytosine arabinoside (ara-C) resistance confers cross-resistance or collateral sensitivity to other classes of anti-leukemic drugs. Martin-Aragon S; Mukherjee SK; Taylor BJ; Ivy SP; Fu CH; Ardi VC; Avramis VI Anticancer Res; 2000; 20(1A):139-50. PubMed ID: 10769646 [TBL] [Abstract][Full Text] [Related]
2. Taxotere and vincristine inhibit the secretion of the angiogenesis inducing vascular endothelial growth factor (VEGF) by wild-type and drug-resistant human leukemia T-cell lines. Avramis IA; Kwock R; Avramis VI Anticancer Res; 2001; 21(4A):2281-6. PubMed ID: 11724283 [TBL] [Abstract][Full Text] [Related]
3. Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines. Nuessler V; Stötzer O; Gullis E; Pelka-Fleischer R; Pogrebniak A; Gieseler F; Wilmanns W Leukemia; 1999 Nov; 13(11):1864-72. PubMed ID: 10557064 [TBL] [Abstract][Full Text] [Related]
4. Reversal of cytosine arabinoside (ara-C) resistance by the synergistic combination of 6-thioguanine plus ara-C plus PEG-asparaginase (TGAP) in human leukemia lines lacking or expressing p53 protein. Fu CH; Martin-Aragon S; Weinberg KI; Ardi VC; Danenberg PV; Avramis VI Cancer Chemother Pharmacol; 2001 Aug; 48(2):123-33. PubMed ID: 11561778 [TBL] [Abstract][Full Text] [Related]
5. [Multidrug resistance mechanisms in cell line HL-60/VCR]. Zhu XH; Li JY; Xia XM; Zhu MQ; Geng MJ; Chen L; Zhang JQ Ai Zheng; 2002 Dec; 21(12):1310-3. PubMed ID: 12520737 [TBL] [Abstract][Full Text] [Related]
6. Development of a double-drug-resistant human leukemia model to cytosine arabinoside and L-asparaginase: evaluation of cross-resistance to other treatment modalities. Majlessipour F; Kwock R; Martin-Aragon S; Weinberg KI; Avramis VI Anticancer Res; 2001; 21(1A):11-22. PubMed ID: 11299723 [TBL] [Abstract][Full Text] [Related]
7. Increased p21/WAF-1 and p53 protein levels following sequential three drug combination regimen of fludarabine, cytarabine and docetaxel induces apoptosis in human leukemia cells. Avramis VI; Nandy P; Kwock R; Solorzano MM; Mukherjee SK; Danenberg P; Cohen LJ Anticancer Res; 1998; 18(4A):2327-38. PubMed ID: 9703875 [TBL] [Abstract][Full Text] [Related]
8. The combination regimen of idarubicin and taxotere is effective against human drug-resistant leukemic cell lines. Majlessipour F; Avramis IA; Kwock R; Weinberg KI; Avrami VI Anticancer Res; 2002; 22(3):1361-8. PubMed ID: 12168812 [TBL] [Abstract][Full Text] [Related]
9. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Huang Y; Ibrado AM; Reed JC; Bullock G; Ray S; Tang C; Bhalla K Leukemia; 1997 Feb; 11(2):253-7. PubMed ID: 9009089 [TBL] [Abstract][Full Text] [Related]
10. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines. Avramis IA; Laug WE; Sausville EA; Avramis VI Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297 [TBL] [Abstract][Full Text] [Related]
11. Mechanisms of taxotere-related drug resistance in pancreatic carcinoma. Liu B; Staren ED; Iwamura T; Appert HE; Howard JM J Surg Res; 2001 Aug; 99(2):179-86. PubMed ID: 11469885 [TBL] [Abstract][Full Text] [Related]
12. The synergism of 6-mercaptopurine plus cytosine arabinoside followed by PEG-asparaginase in human leukemia cell lines (CCRF/CEM/0 and (CCRF/CEM/ara-C/7A) is due to increased cellular apoptosis. Nandy P; Periclou AP; Avramis VI Anticancer Res; 1998; 18(2A):727-37. PubMed ID: 9615712 [TBL] [Abstract][Full Text] [Related]
13. Simultaneous treatment with 1-beta-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells. Takemura H; Urasaki Y; Yoshida A; Fukushima T; Ueda T Cancer Res; 2001 Jan; 61(1):172-7. PubMed ID: 11196156 [TBL] [Abstract][Full Text] [Related]
14. Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines. Ramilo-Torno LV; Avramis VI Cancer Chemother Pharmacol; 1995; 35(3):191-9. PubMed ID: 7805176 [TBL] [Abstract][Full Text] [Related]
15. Characterization of cytarabine-resistant leukemic cell lines established from five different blood cell lineages using gene expression and proteomic analyses. Negoro E; Yamauchi T; Urasaki Y; Nishi R; Hori H; Ueda T Int J Oncol; 2011 Apr; 38(4):911-9. PubMed ID: 21290089 [TBL] [Abstract][Full Text] [Related]
16. Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells. Morgan SE; Kim R; Wang PC; Bhat UG; Kusumoto H; Lu T; Beck WT Oncogene; 2000 Oct; 19(43):5010-9. PubMed ID: 11042688 [TBL] [Abstract][Full Text] [Related]
18. Overcoming of multidrug resistance by introducing the apoptosis gene, bcl-Xs, into MRP-overexpressing drug resistant cells. Ohi Y; Kim R; Toge T Int J Oncol; 2000 May; 16(5):959-69. PubMed ID: 10762632 [TBL] [Abstract][Full Text] [Related]
19. Resistance to apoptotic cell death in a drug resistant T cell leukaemia cell line. Geyp M; Ireland CM; Pittman SM Leukemia; 1996 Mar; 10(3):447-55. PubMed ID: 8642860 [TBL] [Abstract][Full Text] [Related]
20. Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein. Stam RW; van den Heuvel-Eibrink MM; den Boer ML; Ebus ME; Janka-Schaub GE; Allen JD; Pieters R Leukemia; 2004 Jan; 18(1):78-83. PubMed ID: 14574327 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]